LivaNova Expands OSA Care With FDA-Approved aura6000 System
LivaNova LIVN recently received premarket approval from the FDA for its aura6000 system to treat adults with moderate to severe Obstructive Sleep Apnea (OSA). The system uses proximal hypoglossal nerve stimulation (p-HGNS), an advanced neurostimulation approach, to manage OSA in patients with an apnea-hypopnea index (AHI) ranging from 15 to 65 years. It is specifically intended for individuals who have not responded to, cannot tolerate or are unsuitable for first-line treatments like positive airway pressure.
Per management, the FDA approval of the aura6000 represents a transformative moment for the company and a major step forward for patients whose OSA remains inadequately managed. LIVN’s p-HGNS therapy was assessed for safety and effectiveness in the OSPREY randomized controlled trial, demonstrating significant outcomes and durable benefits over time. The p-HGNS is the first and only HGNS device approved by the FDA without a contraindication or warning related to CCC and without the need for a pre-implantation DISE (drug-induced sleep endoscopy).
Likely Trend of LIVNLIVN-- Stock Following the News
Shares of LIVN have lost 1.8% since the announcement on Thursday. Over the past six months, shares of the company have climbed 19.3% against the industry’s 3.6% decline. However, the S&P 500 has risen 0.6% during the same timeframe.
In the long run, the FDA approval of the aura6000 system strengthens LivaNova’s competitive position in the neurostimulation and sleep apnea markets by unlocking a new revenue stream driven by device sales, procedural adoption and patient follow-ups. It improves visibility in the company’s commercialization prospects as it advances toward launching a next-generation system with enhanced capabilities and broader patient reach. At the same time, the decision validates a promising alternative for patients with OSA who are underserved by existing therapies. With global awareness and diagnosis of sleep apnea continuing to grow, innovations like the aura6000 system have the potential to reshape treatment standards, deliver better sleep, improve health outcomes and provide a higher quality of life.
LIVN currently has a market capitalization of $3.46 billion.
Image Source: Zacks Investment Research
More on the aura6000 System
The aura6000 system introduces p-HGNS, a differentiated therapy that targets the hypoglossal nerve, which controls airway muscles and maintains an open airway during sleep, addressing the root cause of apnea events.
Unlike conventional therapies, LivaNova’s approach utilizes six electrodes placed along the proximal nerve trunk, enabling broader muscle engagement and personalized therapy adjustments through its PolySync algorithm.
The FDA approval is backed by robust data from the OSPREY randomized controlled trial. Results demonstrated sustained improvements across key clinical metrics. Patients receiving p-HGNS therapy experienced a substantial reduction in AHI, with median levels dropping from 34.3 events per hour at baseline to 11.6 in seven months. Oxygen desaturation index also improved, reinforcing the therapy’s physiological impact.
65% of patients met responder criteria at 12 months, defined as achieving at least a 50% reduction in AHI and reaching clinically safer levels. These outcomes were consistent even among patients with complex airway conditions such as complete concentric collapse, highlighting the therapy’s broad applicability.
Building on this approval, LivaNovaLIVN-- is already advancing a next-generation OSA device. Planned enhancements include MRI compatibility, remote configuration capabilities and a rechargeable battery with a lifespan of up to 15 years.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the sleep apnea devices market is valued at $7.62 billion in 2026 and is expected to witness a CAGR of 7% through 2034.
Factors like the cumulative incidence of obstructive sleep apnea across the world, swelling consciousness for the target condition, and snowballing patient adherence to positive airway pressure machines and initial disease diagnosis are spurring the demand for sleep apnea devices.
Other News
In November, LivaNova announced that the U.S. Centers for Medicare & Medicaid Services had upgraded reimbursement classifications for its VNS Therapy, a neuromodulation treatment used in patients aged four and above with Drug-Resistant Epilepsy and focal seizures. Beginning Jan. 1, 2026, VNS Therapy for new patient implants (NPIs) has been assigned to New Technology Ambulatory Payment Classification 1580, while end-of-service procedures have been moved from Level 4 to Level 5 APC.
Medicare reimbursement rates for these procedures will rise by 48% for NPIs and 47% for EOS procedures compared to 2025 levels. This will improve hospital economics, reduce cost barriers and support broader patient access to treatment.
LIVN’s Zacks Rank & Other Key Picks
Currently, LIVN has a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Phibro Animal Health PAHC, Intuitive Surgical ISRG and Cardinal Health CAH.
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report
LivaNova PLC (LIVN): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Comentarios
Aún no hay comentarios